Company: SYRA
Filing Date: 2025-03-11
Form Type: 10-K
Source: 0001493152-25-009873
Chunk: 272

Company: Syra Health Corp
Filing Date: 2025-03-11
Form: 10-K
Item: Item 1A
Chunk 272
---
 trading on its exchange, which could limit investors’ ability to make transactions in
our Class A common stock and subject us to additional trading restrictions.

Our
Class A common stock is listed on the Nasdaq Capital Market and we expect to meet the minimum initial listing standards set forth in
the Nasdaq listing standards, we cannot assure you that our Class A common stock will be, or will continue to be, listed on Nasdaq in
the future. In order to continue listing our Class A common stock on Nasdaq, we must maintain certain financial, distribution and stock
price levels and must maintain a minimum number of holders of our Class A common stock.

If
Nasdaq delists our Class A common stock and we are not able to list our Class A common stock on another national securities exchange,
a reduction in some or all of the following may occur, each of which could have a material adverse effect on our stockholders:

    ●
    the
    liquidity of our Class A common stock;

    ●
    the
    market price of our Class A common stock;

    ●
    our
    ability to obtain financing for the continuation of our operations;

    ●
    the
    number of investors that will consider investing in our Class A common stock;

    ●
    the
    number of market makers in our Class A common stock;

    ●
    the
    availability of information concerning the trading prices and volume of our Class A common stock; and

    ●
    the
    number of broker-dealers willing to execute trades in shares of our Class A common stock.

The
market price of our Class A common stock may be volatile and fluctuate substantially, which could result in substantial losses for holders
of our Class A common stock.

The
market price of our Class A common stock is likely to be highly volatile and may be subject to wide fluctuations in response to a variety
of factors, including the following:

    ●
    failure
    to successfully develop and commercialize our digital health platforms;

    ●
    regulatory
    or legal developments in the United States;

    ●
    changes
    in physician, hospital or healthcare provider practices that may make our solutions less useful;

-20-

    ●
    inability
    to obtain additional funding;

    ●
    failure
    to meet or exceed financial projections we provide to the public;

    ●
    failure
    to meet or exceed the estimates and projections of the investment community;

    ●
    changes